+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Active Pharmaceutical Ingredients CDMO Market Research Report by Drug, Synthesis, Product, Workflow, Application, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 250 Pages
  • October 2022
  • Region: Global
  • 360iResearch™
  • ID: 5437766
UP TO OFF until Dec 31st 2022
The Global Active Pharmaceutical Ingredients CDMO Market size was estimated at USD 142.47 billion in 2021, USD 155.31 billion in 2022, and is projected to grow at a CAGR of 9.18% to reach USD 241.41 billion by 2027.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Active Pharmaceutical Ingredients CDMO to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug, the market was studied across Generics and Innovative.
  • Based on Synthesis, the market was studied across Biotech and Synthetic.
  • Based on Product, the market was studied across Antibody Drug Conjugate (ADC), Highly Potent Active Pharmaceutical Ingredient (HP-API), and Traditional Active Pharmaceutical Ingredient (Traditional API).
  • Based on Workflow, the market was studied across Clinical and Commercial.
  • Based on Application, the market was studied across Cardiovascular, Diabetes, Glaucoma, Hormonal, and Oncology.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. The ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

The publisher continuously monitors and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Active Pharmaceutical Ingredients CDMO market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Active Pharmaceutical Ingredients CDMO Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Active Pharmaceutical Ingredients CDMO Market, including AbbVie, Inc., Albemarle Corporation, Boehringer Ingelheim, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cambrex, Catalent, Cipla, Inc., Corden Pharma., Lonza, Merck & Co., Inc., Piramal Pharma Solutions, ReciPharm, Samsung Biologics, Siegfried, Teva Pharmaceutical Industries Ltd., and ThermoFisher Pantheon.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Active Pharmaceutical Ingredients CDMO Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Active Pharmaceutical Ingredients CDMO Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Active Pharmaceutical Ingredients CDMO Market?
4. What is the competitive strategic window for opportunities in the Global Active Pharmaceutical Ingredients CDMO Market?
5. What are the technology trends and regulatory frameworks in the Global Active Pharmaceutical Ingredients CDMO Market?
6. What is the market share of the leading vendors in the Global Active Pharmaceutical Ingredients CDMO Market?
7. What modes and strategic moves are considered suitable for entering the Global Active Pharmaceutical Ingredients CDMO Market?
Frequently Asked Questions about the Global Active Pharmaceutical Ingredients CDMO Market

What is the estimated value of the Global Active Pharmaceutical Ingredients CDMO Market?

The Global Active Pharmaceutical Ingredients CDMO Market was estimated to be valued at $142.47 Billion in 2021.

What is the growth rate of the Global Active Pharmaceutical Ingredients CDMO Market?

The growth rate of the Global Active Pharmaceutical Ingredients CDMO Market is 9.1%, with an estimated value of $241.41 Billion by 2027.

What is the forecasted size of the Global Active Pharmaceutical Ingredients CDMO Market?

The Global Active Pharmaceutical Ingredients CDMO Market is estimated to be worth $241.41 Billion by 2027.

Who are the key companies in the Global Active Pharmaceutical Ingredients CDMO Market?

Key companies in the Global Active Pharmaceutical Ingredients CDMO Market include AbbVie, Inc., Albemarle Corporation, Boehringer Ingelheim, Boehringer Ingelheim International GmbH, Bristol, Myers Squibb Company, Cambrex, Catalent and Corden Pharma..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing pharmaceutical R&D investment
5.1.1.2. Rising demand for generic drugs and biologic innovation
5.1.1.3. Growth of small molecules, rising active pharmaceutical ingredient (API) complexity
5.1.2. Restraints
5.1.2.1. Compliance issues while outsourcing
5.1.3. Opportunities
5.1.3.1. Expanding consumption of biopharmaceuticals
5.1.3.2. Rising prevalence of cancer and increasing sophistication in oncology drug research
5.1.4. Challenges
5.1.4.1. Stringent government regulations
5.2. Cumulative Impact of COVID-19
6. Active Pharmaceutical Ingredients CDMO Market, by Drug
6.1. Introduction
6.2. Generics
6.3. Innovative
7. Active Pharmaceutical Ingredients CDMO Market, by Synthesis
7.1. Introduction
7.2. Biotech
7.3. Synthetic
8. Active Pharmaceutical Ingredients CDMO Market, by Product
8.1. Introduction
8.2. Antibody Drug Conjugate (ADC)
8.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
8.4. Traditional Active Pharmaceutical Ingredient (Traditional API)
9. Active Pharmaceutical Ingredients CDMO Market, by Workflow
9.1. Introduction
9.2. Clinical
9.3. Commercial
10. Active Pharmaceutical Ingredients CDMO Market, by Application
10.1. Introduction
10.2. Cardiovascular
10.3. Diabetes
10.4. Glaucoma
10.5. Hormonal
10.6. Oncology
11. Americas Active Pharmaceutical Ingredients CDMO Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Active Pharmaceutical Ingredients CDMO Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Active Pharmaceutical Ingredients CDMO Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. AbbVie, Inc.
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Albemarle Corporation
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Boehringer Ingelheim
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Boehringer Ingelheim International GmbH
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Bristol-Myers Squibb Company
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Cambrex
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Catalent
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Cipla, Inc.
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Corden Pharma.
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Lonza
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Merck & Co., Inc.
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Piramal Pharma Solutions
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. ReciPharm
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Samsung Biologics
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Siegfried
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Teva Pharmaceutical Industries Ltd.
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. ThermoFisher Pantheon
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2021 VS 2027
FIGURE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2027
FIGURE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET DYNAMICS
FIGURE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2021 VS 2027 (%)
FIGURE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2021 VS 2027 (USD BILLION)
FIGURE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET COMPETITIVE STRATEGIC WINDOW, BY DRUG, 2027
FIGURE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENERICS, 2018-2027 (USD BILLION)
FIGURE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY INNOVATIVE, 2018-2027 (USD BILLION)
FIGURE 16. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2021 VS 2027 (%)
FIGURE 17. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2021 VS 2027 (USD BILLION)
FIGURE 18. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET COMPETITIVE STRATEGIC WINDOW, BY SYNTHESIS, 2027
FIGURE 19. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOTECH, 2018-2027 (USD BILLION)
FIGURE 20. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHETIC, 2018-2027 (USD BILLION)
FIGURE 21. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2021 VS 2027 (%)
FIGURE 22. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2021 VS 2027 (USD BILLION)
FIGURE 23. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET COMPETITIVE STRATEGIC WINDOW, BY PRODUCT, 2027
FIGURE 24. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANTIBODY DRUG CONJUGATE (ADC), 2018-2027 (USD BILLION)
FIGURE 25. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT (HP-API), 2018-2027 (USD BILLION)
FIGURE 26. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENT (TRADITIONAL API), 2018-2027 (USD BILLION)
FIGURE 27. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2021 VS 2027 (%)
FIGURE 28. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2021 VS 2027 (USD BILLION)
FIGURE 29. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET COMPETITIVE STRATEGIC WINDOW, BY WORKFLOW, 2027
FIGURE 30. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL, 2018-2027 (USD BILLION)
FIGURE 31. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL, 2018-2027 (USD BILLION)
FIGURE 32. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 33. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD BILLION)
FIGURE 34. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET COMPETITIVE STRATEGIC WINDOW, BY APPLICATION, 2027
FIGURE 35. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CARDIOVASCULAR, 2018-2027 (USD BILLION)
FIGURE 36. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DIABETES, 2018-2027 (USD BILLION)
FIGURE 37. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GLAUCOMA, 2018-2027 (USD BILLION)
FIGURE 38. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HORMONAL, 2018-2027 (USD BILLION)
FIGURE 39. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ONCOLOGY, 2018-2027 (USD BILLION)
FIGURE 40. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 41. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 42. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 43. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 44. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 45. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 46. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 47. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 48. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 49. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 50. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 51. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 52. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 53. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 54. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 55. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 56. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 57. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 58. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 59. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 60. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 61. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 62. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 63. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 64. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 65. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 66. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 67. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 68. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 69. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 70. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 71. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 72. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 73. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 74. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 75. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 76. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 77. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 78. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 79. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 80. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 81. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 82. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 83. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 84. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 85. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 86. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 87. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 88. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 89. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 90. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 91. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 92. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 93. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 94. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 95. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021
List of Tables
TABLE 1. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2021
TABLE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY REGION, 2018-2027 (USD BILLION)
TABLE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2027 (USD BILLION)
TABLE 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENERICS, 2018-2027 (USD BILLION)
TABLE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENERICS, BY REGION, 2018-2027 (USD BILLION)
TABLE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GENERICS, BY REGION, 2018-2027 (USD BILLION)
TABLE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY INNOVATIVE, 2018-2027 (USD BILLION)
TABLE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY INNOVATIVE, BY REGION, 2018-2027 (USD BILLION)
TABLE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY INNOVATIVE, BY REGION, 2018-2027 (USD BILLION)
TABLE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOTECH, 2018-2027 (USD BILLION)
TABLE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOTECH, BY REGION, 2018-2027 (USD BILLION)
TABLE 16. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY BIOTECH, BY REGION, 2018-2027 (USD BILLION)
TABLE 17. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHETIC, 2018-2027 (USD BILLION)
TABLE 18. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2027 (USD BILLION)
TABLE 19. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2027 (USD BILLION)
TABLE 20. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 21. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANTIBODY DRUG CONJUGATE (ADC), 2018-2027 (USD BILLION)
TABLE 22. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANTIBODY DRUG CONJUGATE (ADC), BY REGION, 2018-2027 (USD BILLION)
TABLE 23. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ANTIBODY DRUG CONJUGATE (ADC), BY REGION, 2018-2027 (USD BILLION)
TABLE 24. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT (HP-API), 2018-2027 (USD BILLION)
TABLE 25. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT (HP-API), BY REGION, 2018-2027 (USD BILLION)
TABLE 26. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT (HP-API), BY REGION, 2018-2027 (USD BILLION)
TABLE 27. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENT (TRADITIONAL API), 2018-2027 (USD BILLION)
TABLE 28. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENT (TRADITIONAL API), BY REGION, 2018-2027 (USD BILLION)
TABLE 29. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENT (TRADITIONAL API), BY REGION, 2018-2027 (USD BILLION)
TABLE 30. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 31. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL, 2018-2027 (USD BILLION)
TABLE 32. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL, BY REGION, 2018-2027 (USD BILLION)
TABLE 33. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CLINICAL, BY REGION, 2018-2027 (USD BILLION)
TABLE 34. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL, 2018-2027 (USD BILLION)
TABLE 35. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2027 (USD BILLION)
TABLE 36. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2027 (USD BILLION)
TABLE 37. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 38. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CARDIOVASCULAR, 2018-2027 (USD BILLION)
TABLE 39. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2027 (USD BILLION)
TABLE 40. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2027 (USD BILLION)
TABLE 41. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DIABETES, 2018-2027 (USD BILLION)
TABLE 42. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DIABETES, BY REGION, 2018-2027 (USD BILLION)
TABLE 43. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DIABETES, BY REGION, 2018-2027 (USD BILLION)
TABLE 44. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GLAUCOMA, 2018-2027 (USD BILLION)
TABLE 45. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2027 (USD BILLION)
TABLE 46. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2027 (USD BILLION)
TABLE 47. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HORMONAL, 2018-2027 (USD BILLION)
TABLE 48. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HORMONAL, BY REGION, 2018-2027 (USD BILLION)
TABLE 49. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY HORMONAL, BY REGION, 2018-2027 (USD BILLION)
TABLE 50. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ONCOLOGY, 2018-2027 (USD BILLION)
TABLE 51. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2027 (USD BILLION)
TABLE 52. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2027 (USD BILLION)
TABLE 53. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 54. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2027 (USD BILLION)
TABLE 55. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 56. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 57. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 58. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 59. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 60. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 61. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 62. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 63. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 64. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 65. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 66. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 67. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 68. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 69. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 70. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 71. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 72. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 73. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 74. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 75. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 76. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 77. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 78. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 79. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 80. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 81. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 82. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 83. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 84. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 85. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY STATE, 2018-2027 (USD BILLION)
TABLE 86. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 87. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 88. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 89. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 90. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 91. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 92. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2027 (USD BILLION)
TABLE 93. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 94. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 95. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 96. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 97. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 98. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 99. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 100. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 101. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 102. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 103. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 104. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 105. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 106. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 107. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 108. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 109. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 110. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 111. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 112. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 113. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 114. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 115. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 116. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 117. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 118. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 119. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 120. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 121. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 122. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 123. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 124. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 125. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 126. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 127. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 128. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 129. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 130. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 131. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 132. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 133. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 134. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 135. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 136. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 137. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 138. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 139. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 140. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 141. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 142. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 143. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 144. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 145. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 146. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 147. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 148. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 149. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 150. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 151. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 152. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 153. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 154. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 155. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 156. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 157. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 158. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 159. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 160. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 161. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 162. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 163. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 164. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 165. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 166. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 167. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 168. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 169. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY COUNTRY, 2018-2027 (USD BILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 177. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 178. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 179. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 180. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 181. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 182. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 183. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 184. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 185. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 186. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 187. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 188. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 189. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 190. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 191. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 192. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 193. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 194. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 195. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 196. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 197. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 198. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 199. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 200. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 201. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 202. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 203. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 204. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 205. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 206. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 207. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 208. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 209. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 210. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 211. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 212. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 213. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 214. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 215. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 216. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 217. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 218. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 219. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 220. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 221. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 222. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 223. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 224. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 225. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 226. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 227. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 228. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 229. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 230. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 231. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 232. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 233. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 234. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 235. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 236. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 237. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 238. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 239. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 240. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 241. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 242. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 243. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 244. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 245. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 246. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 247. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 248. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 249. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 250. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 251. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 252. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 253. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 254. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 255. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 256. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 257. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 258. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 259. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 260. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 261. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 262. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 263. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 264. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 265. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 266. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 267. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 268. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 269. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 270. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 271. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 272. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 273. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 274. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 275. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 276. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 277. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 278. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 279. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 280. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 281. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 282. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 283. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 284. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 285. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 286. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 287. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 288. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 289. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 290. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 291. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 292. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 293. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 294. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 295. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFLOW, 2018-2027 (USD BILLION)
TABLE 296. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY APPLICATION, 2018-2027 (USD BILLION)
TABLE 297. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 298. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY DRUG, 2018-2027 (USD BILLION)
TABLE 299. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY SYNTHESIS, 2018-2027 (USD BILLION)
TABLE 300. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 301. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS CDMO MARKET SIZE, BY WORKFL

Companies Mentioned

  • AbbVie, Inc.
  • Albemarle Corporation
  • Boehringer Ingelheim
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cambrex
  • Catalent
  • Cipla, Inc.
  • Corden Pharma.
  • Lonza
  • Merck & Co., Inc.
  • Piramal Pharma Solutions
  • ReciPharm
  • Samsung Biologics
  • Siegfried
  • Teva Pharmaceutical Industries Ltd.
  • ThermoFisher Pantheon

Methodology

Loading
LOADING...